KS
Kanika Shah Wadhwa
About Kanika Shah Wadhwa
Data last updated:
Kanika Shah Wadhwa is a Whole-Time Director at Glaxosmithkline Asia Private Limited (since 2019) and Whole-Time Director at Haleon India Private Limited (since 2019). The companies operate in Healthcare. The largest current company by reported revenue is Glaxosmithkline Asia Private Limited at ₹2,362 Cr (FY 2023).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Glaxosmithkline Asia Private Limited U99999PB1995PTC028476 | Whole-Time Director | 12 Mar 2019 | 1995 | ₹2,362 Cr (FY 2023) | Active |
 Haleon India Private Limited U99999DL1995PTC469964 | Whole-Time Director | 12 Mar 2019 | 1995 | Active |
Board colleagues of Kanika Shah Wadhwa
| Name | DIN | Company | Designation |
|---|---|---|---|
| Anurita Chopra | 07607315 | Glaxosmithkline Asia Private Limited | Whole-Time Director |
| Nitin Mathur | 09046346 | Glaxosmithkline Asia Private Limited , Haleon India Private Limited | Whole-Time Director |
| Ramesh Chander Gupta | 02314913 | Glaxosmithkline Asia Private Limited , Haleon India Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kanika Shah Wadhwa
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kanika Shah Wadhwa
Kanika Shah Wadhwa currently holds 2 directorships: Glaxosmithkline Asia Private Limited (Whole-Time Director, since 12 Mar 2019, revenue ₹2,362 Cr (FY 2023)); Haleon India Private Limited (Whole-Time Director, since 12 Mar 2019).
Kanika Shah Wadhwa was first appointed on 12 Mar 2019 as Whole-Time Director at Glaxosmithkline Asia Private Limited.
The current boards of Kanika Shah Wadhwa's companies include Anurita Chopra (Glaxosmithkline Asia Private Limited), Nitin Mathur (Glaxosmithkline Asia Private Limited), Ramesh Chander Gupta (Glaxosmithkline Asia Private Limited).